Stock HUGE FSD PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

News FSD Pharma Inc.

Equities

HUGE

CA35954B4047

Delayed Canadian Securities Exchange
Other stock markets
 12:09:23 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.65 CAD +1.56% Intraday chart for FSD Pharma Inc. -5.80% -45.83%
Apr. 08 FSD Pharma Receives Nasdaq Non-Compliance Notice MT
Mar. 29 FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FSD Pharma Provides another Update on Celly Nu's Anticipated Launch of unbuzzd
AQ
FSD Pharma : Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products - Form 6-K
PU
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
AQ
FSD Pharma Receives Nasdaq Non-Compliance Notice
MT
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
NE
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
FSD Pharma Signs the Agreement With iNGENu CRO to Conduct a Clinical Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adults
AQ
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO
MT
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
MT
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd
MT
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd
CI
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 at Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum
AQ
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum
MT
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
MT
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
MT
FSD Pharma : Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum - Form 6-K
PU
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum
CI
FSD Pharma Announces Debt Settlement
AQ
FSD Pharma Signs Agreement with Ingenu CRO to Conduct a Clinical Trial to Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd
AQ
MT Newswires Canada Stocks To Watch: SSR Mining, Tricon Residential; Imperial Oil; FSD Pharma
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HUGE Stock
  4. News FSD Pharma Inc.